Results 1 to 10 of about 26,025 (223)

Venetoclax as a trigger for autoimmune hemolytic anemia in secondary acute myeloid leukemia: A case report [PDF]

SAGE Open Medical Case Reports
Venetoclax, a BCL-2 inhibitor used in chronic lymphocytic leukemia and acute myeloid leukemia, has been rarely associated with autoimmune hemolytic anemia, mostly in chronic lymphocytic leukemia.
Karima Benallaoua, Pierre Lacoeuilhe, Benoît Gendrot, Sahra Muhammad, Guillemette Fouquet   +4 more
doaj   +2 more sources

Pharmacological boosting of azacitidine/venetoclax in acute myeloid leukemia [PDF]

Blood Neoplasia
: Azacitidine/venetoclax is the standard treatment for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. Cytochrome P450 3A4 (CYP3A4) is the major metabolizing enzyme for venetoclax, and its inhibition can boost venetoclax.
Niels Westra, Elena Ropero Cerro, Edwin Schilder, Marjolijn N. Lub-de Hooge, Daan J. Touw, Jos G. W. Kosterink, Dana A. Chitu, Emanuele Ammatuna, Saskia K. Klein, Peter E. Westerweel, Marloes Cuijpers, Marjan Cruijsen, Maarten M. F. Corsten, Canan Alhan, Lidwine Tick, Jan Jacob Schuringa, Gerwin Huls, Carolien M. Woolthuis, Thijs H. Oude Munnink   +18 more
doaj   +2 more sources

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination

Pharmaceutics, 2022
Venetoclax, a BCL-2 inhibitor used to treat certain hematological cancers, exhibits low oral bioavailability and high interpatient pharmacokinetic variability. Venetoclax is commonly administered with prophylactic antifungal drugs that may result in drug
Eric D Eisenmann, Dominique A Garrison, Zahra Talebi   +2 more
exaly   +3 more sources

Venetoclax [PDF]

Reactions Weekly, 2020
  +9 more sources

Progress in understanding the mechanisms of resistance to BCL-2 inhibitors

Experimental Hematology & Oncology, 2022
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial apoptotic pathway.
Yilan Xu, Haige Ye
doaj   +1 more source

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin

Clinical and Translational Science, 2020
Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro. To quantify the impact of CYP3A inhibition by ritonavir on venetoclax disposition and P‐gp inhibition by venetoclax on ...
Ali A. Alhadab, Ahmed Hamed Salem, Kevin J. Freise   +2 more
doaj   +1 more source

Venetoclax

Reactions Weekly
  +16 more sources

Bone marrow senescence and the microenvironment of hematological malignancies [PDF]

, 2020
Senescence is the irreversible arrest of cell proliferation that has now been shown to play an important role in both health and disease. With increasing age senescent cells accumulate throughout the body, including the bone marrow and this has been ...
Bowles, Kristian M., Hellmich, Charlotte, Moore, Jamie A., Rushworth, Stuart A.   +3 more
core   +1 more source

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

Haematologica, 2020
Venetoclax is a promising agent in the treatment of acute myeloid leukemia, though its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim upregulation, and DNA damage have been identified as potential ways to enhance ...
Xinyu Li, Yongwei Su, Katie Hege, Gerard Madlambayan, Holly Edwards, Tristan Knight, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jay Yang, Regan Miller, Guan Wang, Lijing Zhao, Yue Wang, Hai Lin, Jeffrey W. Taub, Yubin Ge   +17 more
doaj   +1 more source

Constitutive IP₃ signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP₃ receptor disruptor BIRD-2 [PDF]

, 2018
Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5 ...
Akl, Haidar, Baes, Myriam, Bittremieux, Mart, Bootman, Martin D., Bultynck, Geert, De Smedt, Humbert, Dubron, Kathia, Efremov, Dimitar G., Janssens, Ann, La Rovere, Rita M., Laurenti, Luca, Martines, Claudio, Mikoshiba, Katsuhiko, Morciano, Giampaolo, Parys, Jan B., Pinton, Paolo, Rietdorf, Katja, Vandenberghe, Peter, Welkenhuyzen, Kirsten   +18 more
core   +3 more sources